Healthcare Industry News: NSCLC
News Release - February 23, 2010
BSD Medical Reports Publication of Chinese Study Using the BSD-2000 Hyperthermia System to Treat Lung CancerSALT LAKE CITY--(HSMN NewsFeed)--BSD Medical Corporation (NASDAQ: BSDM ) (the “Company” or “BSD”) today announced that a study titled “BSD2000 Deep Hyperthermia Combined with Chemotherapy of PT regimen in Patients with Non-small Cell Lung Cancer” has been published in the current issue of The Chinese Journal of Lung Cancer (February 2010;13(2):132–135) by Yang, Zhao, and Wang. The article can be accessed at https://www.mdlinx.com/internalmdlinx/login.cfm (free online registration required). The clinical study, conducted at a prestigious hospital in China, involved 60 patients with non-small cell lung cancer (NSCLC) who were randomized to receive either chemotherapy (cisplatin and paclitaxel) combined with hyperthermia (delivered using the BSD-2000 Hyperthermia System) or chemotherapy without hyperthermia.
The researchers compared the short-term tumor regression rate, side effects and quality of life improvement between the two groups. Efficacy was based on World Health Organization standards and included those patients who had a complete response (CR=100% tumor disappearance) or a partial response (PR=50% to <100% tumor disappearance). The percentage of patients who had a CR plus PR and an improved quality of life after three cycles of treatment was significantly increased by the addition of hyperthermia (63.33% and 76.67%, respectively, for patients treated with hyperthermia and chemotherapy vs. 36.67% and 40.00% for those treated with chemotherapy alone, p<0.05). The main side effects were myelosuppression and gastrointestinal reactions, and there was no significant difference between the two groups for side effects (p>0.05).
The researchers concluded that “BSD2000 deep hyperthermia combined with chemotherapy in patients with NSCLC can significantly increase the efficacy, response rate and quality of life improvement and without increasing side effects compared to chemotherapy alone.”
Lung cancer is the leading cause of cancer-related mortality not only in the United States but also around the world. Lung cancer is the fastest growing type of cancer in China and is the leading cause of death from cancer in men and the second leading cause of death from cancer in women in China. Non-small cell lung cancer is the most common type of lung cancer, comprising 80% of all cases.
With the assistance of Dalian Orientech, a privately owned company and its exclusive Chinese distributor, BSD obtained Chinese regulatory (SFDA) approval for the BSD-2000 in 2005, allowing Dalian Orientech to market and sell the system to hospitals throughout China. BSD has placed 17 BSD-2000 systems with Dalian Orientech customers in China.
Hyperthermia has been used in China for the treatment of cancer for many years, and several thousand simple hyperthermia cancer therapy systems are in place in China. The market objective for BSD in China is to continue to expand and upgrade the existing market for clinical hyperthermia equipment to the advanced features of the BSD-2000 Hyperthermia System.
About the Researchers
The research was conducted by medical researchers from Liaocheng People's Hospital in China who are at the forefront of oncology research in China. The hospital has received certification from the governing hospital group in China permitting it to participate in key clinical trials. The 2,000 bed hospital has a state-of-the-art cancer treatment facility and is the main cancer treatment center in this city of over 5.5 million people.
About BSD Medical Corporation
BSD Medical Corporation is a leading developer of systems used to deliver precision-focused microwave/RF energy to diseased sites in the body, including cancer. Its treatments are used to kill cancer directly and increase the effectiveness of companion radiation treatments for certain tumors. The BSD-2000 is restricted to investigational use in the United States. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
Source: BSD Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.